VIP PLGA Microparticle Release for Local Immune Tolerance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for immunological disorders and transplantation rejection reactions, such as periodontal disease and tissue transplant rejection, rely on long-term immunosuppressive drugs that cause significant side effects and systemic vulnerability, necessitating a method to induce regulatory T cells without systemic immunosuppression.

Innovation Solution

The use of custom-designed microparticles containing vasoactive intestinal peptide (VIP) to induce regulatory T cells by controlled release, utilizing a combination of polymers with varying molecular weights and a mathematical algorithm to optimize the microparticle composition and release profile.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If long-term immunosuppressive drugs are administered to prevent transplantation rejection and treat immunological disorders, then rejection reactions are reduced, but significant side effects and systemic vulnerability increase

Engineering Contradiction:

Improvetransplantation rejection preventionVSAvoidside effects and systemic vulnerability

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention segments the immunosuppressive effect by using microparticles that locally deliver vasoactive intestinal peptide (VIP) to specific tissues, rather than administering systemic immunosuppressive drugs. This localized delivery achieves immunosuppression at the target site while avoiding widespread systemic effects.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention uses vasoactive intestinal peptide (VIP) as an intermediary substance to induce regulatory T cells. Instead of directly administering traditional immunosuppressive drugs, VIP serves as a mediator that naturally induces regulatory T cells, which then provide the immunosuppressive effect, thereby reducing direct drug toxicity.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If microparticles with controlled VIP release are used to induce regulatory T cells, then systemic immunosuppression is avoided, but manufacturing complexity increases

Engineering Contradiction:

Improvesystemic immunosuppression avoidanceVSAvoidmicroparticle composition and release control

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The invention controls VIP release by changing physical parameters of the microparticle system, specifically using polymer degradation rates and microparticle size to regulate the release profile. This allows controlled release without complex active control mechanisms.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The microparticles are designed to self-regulate VIP release through controlled degradation of the polymer matrix. The system uses its own structural breakdown to control drug release, eliminating the need for external control mechanisms or complex active release systems.

Inventive Principle:

Principle #25Self-service

3Duration of action of moving object

If custom-designed microparticles with multiple polymers are synthesized to optimize VIP release, then controlled release profile is achieved, but manufacturing precision requirements increase

Engineering Contradiction:

Improvecontrolled VIP release durationVSAvoidpolymer composition and molecular weight control

Core Design Contradiction:

Duration of action of moving objectVSManufacturing precision

Solution Approach 1:

The invention uses composite polymer materials with different molecular weights (combining fast-degrading and slow-degrading polymers) to achieve controlled VIP release. This composite approach allows tuning of release profiles through material selection rather than requiring extreme manufacturing precision.

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The invention achieves different degradation rates in different regions of the microparticle structure by using polymers with varying molecular weights. This creates local quality differences within the microparticle that control the temporal profile of VIP release, with faster release from some regions and slower release from others.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach effectively induces regulatory T cells, reducing disease symptoms and promoting immunological tolerance, potentially eliminating the need for long-term immunosuppressive drugs and their side effects.

Implementation Method 1

controlled VIP release from custom designed microparticles

Methodology Applied

Scientific EffectControlled release:

Implementation Method 2

utilizing a combination of polymers with varying molecular weights

Methodology Applied

Scientific EffectPolymer degradation: Decomposition (biological)

Data Source

PatentUS20260014231A1Vasoactive lntestinal Peptide Release From Microparticles

Publication Date: 2026.01.15 UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION

AI summary

Controlled release of VIP from PLGA microparticles was accomplished and varied through use of different polymer molecular sizes, addition of solutes to the inner aqueous phase, and use of our computer model. Released VIP from microparticles appeared to be bioactive and caused DCs to produce more CCL22 than DCs treated with blank particles at 7 and 24 hours. Additionally, DCs treated with VIP microparticle releasates recruited higher percentages of FoxP3+ T-cells in in vitro chemotaxis studies. Testing in a mouse model in vivo indicated that VIP microparticles have significant therapeutic potential to treat periodontal disease by reducing the bone loss in infected mice relative to the blank group.